Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections

Effectiveness of the 50-μg mRNA-1273.214 bivalent vaccine against SARS-CoV-2 infection was modest at 25% in a matched, retrospective, cohort study in Qatar comparing infection incidence in the bivalent cohort to that in the national no-recent-vaccination resident cohort. XBB* immune evasion, immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemaitelly, Hiam, Ayoub, Houssein H, AlMukdad, Sawsan, Faust, Jeremy S, Tang, Patrick, Coyle, Peter, Yassine, Hadi M, Al Thani, Asmaa A, Al-Khatib, Hebah A, Hasan, Mohammad R, Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H, Latif, Ali N, Shaik, Riyazuddin M, Abdul-Rahim, Hanan F, Nasrallah, Gheyath K, Al-Kuwari, Mohamed G, Butt, Adeel A, Al-Romaihi, Hamad E, Al-Thani, Mohamed H, Al-Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481416/
https://www.ncbi.nlm.nih.gov/pubmed/37555656
http://dx.doi.org/10.1093/jtm/taad106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481416/
https://www.ncbi.nlm.nih.gov/pubmed/37555656
http://dx.doi.org/10.1093/jtm/taad106

Ejemplares similares